USCACA Welcomes Its New President – Shi-Yong Sun, Ph.D.
On August 25th, USCACA Executive Office held a meeting to initiate the election process following the bylaws. The meeting was hosted by USCACA Managing Director, Dr. Li Yan,and General Secretary, Dr. YunGuang Tong. At the meeting, Shiyong Sun, nominated by USCACA Board, was elected as the new President of USCACA unanimously by the Executive Officers. After being elected, Shi-Yong shared his passion and vision for the organization.
We welcome our new President Shi-Yong Sun and thank our past President Qingyi Wei for his exceptional leadership and achievements for the organization.
Shi-Yong Sun, Ph.D.
Department of Hematology and Medical Oncology, Emory Winship Cancer Institute and Emory University School of Medicine, Atlanta, GA, USA Dr. Sun earned his Ph.D. in cancer pharmacology from Peking Union Medical College (PUMC)/Chinese Academy of Medical Sciences (CAMS) in 1990 and late received his postdoctoral training in cancer biology at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, USA. Dr. Sun joined in Emory University (Atlanta, Georgia, USA) in 2003 and was quickly prompted to the rank of a tenured full Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine and Winship Cancer Institute in 2011. He is also a Georgia Research Alliance Distinguished Cancer Scientist and Halpern Research Scholar and now serves as Co-Director of Thoracic Cancer Program of Winship Cancer Institute. Dr. Sun’s research primarily focuses on the following areas: 1) regulation of death receptors, particularly TRAIL receptors, by small therapeutic molecules and their implications in drug-induced apoptosis and cancer therapy; 2) understanding mTOR signaling in cancer and targeting the mTOR axis for cancer therapy; and 3) understanding and managing acquired resistance to third generation EGFR inhibitors (e.g., osimertinib/AZD9291). Dr. Sun has been on the editorial boards of over 30 cancer-related journals and reviewed manuscripts for over 100 scientific journals. He has been actively engaged in evaluating or reviewing grants for over 10 international organizations including different USA NIH/NCI study sections and is now a standing member of Cell Signaling Regulatory System (CSRS) study section (2021-2025). He has published over 170 original research papers in prominent peer-reviewed journals since 1994 in addition to over 30 review, editorial or commentary articles. He has supervised over 30 postdoctoral fellows and 18 visiting students who were Ph.D. or M.D. candidates.
孙士勇教授就职于美国埃默里大学医学院和癌症中心。现为血液和肿瘤内科系终身教授和佐治亚州硏究联盟的杰出癌症研究科学家并担任Winship癌症中心胸部肿瘤项目共同主任。 他所在团队主要致力于研究肿瘤治疗新靶点以及靶向药物作用机理和耐药机制。在研究与细胞凋亡有关的死亡受体和mTOR信号传导通路方面做了大量的工作。最近关注研究第三代表皮生长因子抑制剂在治疗肺癌耐药方面的问题. 孙士勇教授发表SCI原著研究论文170余篇和综述或评论文章30余篇。 以首席研究者（principle investigator）或项目负责人（project leader）身份承担美国国立癌症研究所和国防部等科研项目10余项。他是30多种学术期刊比如Molecular Cancer, BMC Cancer, Molecular Carcinogenesis, Cancer Biology and Therapy, Cancer Prevention Research的副编辑 （associate editor）, 高级编委（senior editor）或者编委 。 担任超过90余种国际SCI期刊的审稿人和10多个国家或机构的基金评审专家。直接指导30多名博士后和17名国外来访博士研究生。